title: Pleiotropic effects of ARB in diabetes mellitus.
abstract: Evidence accumulated to date indicates that inhibition of the rennin-angiotensin system with angiotensin receptor blockers (ARB) may prevent new-onset of diabetes. ARB is also used for the prevention of occurrence and progression of complications in diabetes and diabetic nephropathy. From the results of recent large-scale clinical studies, ARB is considered as a first choice drug in hypertensive patients with diabetes. In this review article, we focus on the effects of ARB on progression and prevention against diabetes as a metabolic-improving agent.
authors.affiliation: Department of Cardiology and Hematology, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Japan.
authors.forename: Shu-ichi
authors.initials: S
authors.lastname: Saitoh
authors.forename: Yasuchika
authors.initials: Y
authors.lastname: Takeishi
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D050260:Carbohydrate Metabolism / Q000187:drug effects; D048909:Diabetes Complications / Q000378:metabolism / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D057911:Angiotensin Receptor Antagonists; D001786:Blood Glucose